Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPN-coated engineered Lactobacillus reuteri
- Development stage
- Phase 2
- Lead developer
- South China University of Technology
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MPN-coated engineered Lactobacillus reuteri is an experimental oral live biotherapeutic product (LBP) developed for the targeted treatment of inflammatory bowel disease (IBD), including ulcerative colitis. The therapeutic platform utilizes the probiotic bacterium *Lactobacillus reuteri* which has been genetically engineered to constitutively express and secrete interleukin-10 (IL-10), a potent anti-inflammatory cytokine. To overcome the challenges of oral delivery, the bacteria are encapsulated within a metal-phenolic network (MPN) coating, typically composed of tannic acid and ferric ions (Fe3+). This protective shell enhances bacterial survival against gastric acid and bile salts while providing intrinsic antioxidant activity by scavenging reactive oxygen species (ROS) at the site of intestinal inflammation. Upon reaching the colon, the engineered bacteria colonize the mucosa and locally deliver IL-10, which modulates the immune response by binding to IL-10 receptors on leukocytes, thereby suppressing pro-inflammatory cytokine production and promoting tissue repair.
- Other names
- Metal-phenolic network-coated engineered Lactobacillus reuteriTannic acid/Fe3+ coated engineered Lactobacillus reuteri
02
Targets
IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on MPN-coated engineered Lactobacillus reuteri.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPN-coated engineered Lactobacillus reuteri.